In people with obesity, fat tissue that processes male hormones differently seems to be linked to having more fat around the waist.
Scientific Claim
In obese adults, higher mRNA levels of AKR1C2 and AKR1C3 in subcutaneous adipose tissue are associated with central obesity (higher waist-to-hip ratio), suggesting local androgen metabolism may relate to abdominal fat patterning.
Original Statement
“Central obesity (waist : hip ratio) was associated with mRNA for AKR1C2 (r = 0·28, P < 0·05) and AKR1C3 (r = 0·38, P < 0·01) but not aromatase (r = 0·06).”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract concludes these enzymes 'predict' fat distribution and are 'determinants' — implying causation. But the design is observational and only shows correlation. Verb strength must be downgraded to association.
More Accurate Statement
“In obese adults, higher mRNA levels of AKR1C2 and AKR1C3 in subcutaneous adipose tissue are associated with central obesity (higher waist-to-hip ratio), though causation cannot be determined from this observational data.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether the association between AKR1C2/AKR1C3 mRNA and waist-to-hip ratio is reproducible across ethnicities, sexes, and metabolic phenotypes.
Whether the association between AKR1C2/AKR1C3 mRNA and waist-to-hip ratio is reproducible across ethnicities, sexes, and metabolic phenotypes.
What This Would Prove
Whether the association between AKR1C2/AKR1C3 mRNA and waist-to-hip ratio is reproducible across ethnicities, sexes, and metabolic phenotypes.
Ideal Study Design
A meta-analysis of 12+ studies measuring subcutaneous AKR1C2 and AKR1C3 mRNA in adults with BMI >25, correlating with waist-to-hip ratio, adjusted for sex, age, insulin resistance, and testosterone levels.
Limitation: Cannot determine if enzyme expression drives fat distribution or is a result of it.
Randomized Controlled TrialLevel 1bWhether inhibiting AKR1C2/AKR1C3 activity reduces central fat accumulation over time.
Whether inhibiting AKR1C2/AKR1C3 activity reduces central fat accumulation over time.
What This Would Prove
Whether inhibiting AKR1C2/AKR1C3 activity reduces central fat accumulation over time.
Ideal Study Design
A double-blind RCT of 80 obese adults (BMI 30–35) randomized to 6 months of a selective AKR1C3 inhibitor vs. placebo, with primary outcome change in visceral fat volume via CT scan and waist-to-hip ratio.
Limitation: Pharmacological inhibition may have off-target systemic effects, confounding results.
Prospective Cohort StudyLevel 2bWhether baseline AKR1C2/AKR1C3 expression predicts future development of central obesity.
Whether baseline AKR1C2/AKR1C3 expression predicts future development of central obesity.
What This Would Prove
Whether baseline AKR1C2/AKR1C3 expression predicts future development of central obesity.
Ideal Study Design
A 7-year prospective cohort of 400 adults aged 25–50 with baseline adipose biopsies measuring AKR1C2/AKR1C3 mRNA and annual waist-to-hip ratio and body composition measurements.
Limitation: Cannot rule out lifestyle or hormonal confounders influencing both enzyme expression and fat distribution.
Evidence from Studies
Supporting (1)
Intra‐adipose sex steroid metabolism and body fat distribution in idiopathic human obesity
This study found that in obese people, higher levels of two specific genes (AKR1C2 and AKR1C3) in belly fat are linked to having more fat around the waist — exactly what the claim says.